~~<i id='6174AA4008'><strike id='6174AA4008'><tt id='6174AA4008'><pre id='6174AA4008'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-09-28 05:26:14 Page View：69695

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Time to name cancers by genetics, not organ of origin, expert says
Next article： After affirmative action ruling, medical educators look to 'holistic review'

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

St. Louis police protesters begin picking up checks in $4.9 million settlement

FILE-ProtestersgatherinSt.Louis,Sept.15,2017,afterajudgefoundawhiteformerSt.Louispoliceofficer,Jason

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

InsitroCEOandfounderDaphneKollerNeilsonBarnard/GettyImagesforTheNewYorkTimesSANFRANCISCO—Ittookonlya